SCHEMBL1807656

SCHEMBL1807656

Nc1ccc(S(N)(=O)=O)cc1S(N)(=O)=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 14/20 0.63
CA1 P00915 10/20 0.63
CA12 O43570 10/20 0.63
CA9 Q16790 10/20 0.63
CA4 P22748 8/20 0.63
CA14 Q9ULX7 8/20 0.63
CA5A P35218 8/20 0.63
CA6 P23280 7/20 0.63
CA7 P43166 7/20 0.63
CA5B Q9Y2D0 7/20 0.63
KDM4E B2RXH2 1/20 0.61
MEN1 O00255 1/20 0.61
GAA P10253 1/20 0.61
MAPT P10636 1/20 0.61
PKM P14618 1/20 0.61
RAB9A P51151 1/20 0.61
KMT2A Q03164 1/20 0.61
CYP2C19 P33261 2/20 0.58
APEX1 P27695 2/20 0.58
CYP2C9 P11712 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5353740 0.85 G6PD (0.56) CA2CA1CA12CA9CA4
SCHEMBL10064161 0.85 KDM4E (0.66) CA2CA1CA12CA9CA4
SCHEMBL4953803 0.82 HTR6 (0.67) CA2CA1CA12CA9CA4
SCHEMBL1806178 0.82 CA2 (0.63) CA2CA1CA12CA9CA4
SCHEMBL29828429 0.81 PKM (0.87) CA2CA1CA12CA9CA4
SCHEMBL1911572 0.81 PKM (0.87) CA2CA1CA12CA9CA4
SCHEMBL393315 0.79 CA2 (0.54) CA2CA1CA12CA9CA4
SCHEMBL31095544 0.79 CA2 (0.54) CA2CA1CA12CA9CA4
SCHEMBL7954618 0.78 CA1 (0.53) CA2CA1CA12CA9CA4
SCHEMBL1809177 0.78 CA2 (0.53) CA2CA1CA12CA9CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114471426-B Refined sulfonamide integrated preparation system 济宁正东化工有限公司 2024-06-11 CN disclosed
US-20220202835-A1 INJECTABLE CLORSULON COMPOSITIONS, METHODS AND USES THEREOF Boehringer Ingelheim Animal Health USA Inc. (US) 2022-06-30 US disclosed
CN-114471426-A Fine sulfanilamide integrated preparation system 济宁正东化工有限公司 2022-05-13 CN disclosed
CN-113507922-A Injectable clorsulon compositions, methods and uses thereof 勃林格殷格翰动物保健美国公司 2021-10-15 CN disclosed
US-8404036-B2 Water-soluble near-infrared absorbing coloring matters and aqueous inks containing same NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2013-03-26 US disclosed
US-20110123784-A1 WATER-SOLUBLE NEAR-INFRARED ABSORBING COLORING MATTERS AND AQUEOUS INKS CONTAINING SAME NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2011-05-26 US disclosed
US-7781613-B2 Substituted N-aminomethylene sulfonamides, production and use thereof as medicaments SANOFI-AVENTIS (FR) 2010-08-24 US disclosed
US-20080069851-A1 SUBSTITUTED N-AMINOMETHYLENE SULFONAMIDES, PRODUCTION AND USE THEREOF AS MEDICAMENTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-03-20 US disclosed
US-7235548-B2 Compounds and their use as positive AMPA receptor modulators NEUROSEARCH A/S (DK) 2007-06-26 US disclosed
US-6943159-B1 Compounds and their use as positive AMPA receptor modulators NEUROSEARCH A/S (DK) 2005-09-13 US disclosed
US-20040043987-A1 Novel compounds and their use as positive AMPA receptor modulators NEUROSEARCH A/S. 2004-03-04 US disclosed
EP-1071426-A2 NOVEL COMPOUNDS AND THEIR USE AS POSITIVE AMPA RECEPTOR MODULATORS NEUROSEARCH A/S (DK) 2001-01-31 EP disclosed
WO-1999042456-A2 NOVEL COMPOUNDS AND THEIR USE AS POSITIVE AMPA RECEPTOR MODULATORS NEUROSEARCH A/S (DK) 1999-08-26 WO disclosed
US-4064239-A LIVER FLUKES MERCK & CO., INC. (US) 1977-12-20 US disclosed
US-4062952-A Substituted benzenedisulfonamides as anthelmintics MERCK & CO., INC. (US) 1977-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220202835-A1 INJECTABLE CLORSULON COMPOSITIONS, METHODS AND USES THEREOF IL5, IL17A, IL33 CA2 1585/4885CA1 916/4885CA12 613/4885
US-20040043987-A1 Novel compounds and their use as positive AMPA receptor modulators GRIK4, GRIA4, GRM2 CA2 365/4885CA1 388/4885CA12 1624/4885
US-20080069851-A1 SUBSTITUTED N-AMINOMETHYLENE SULFONAMIDES, PRODUCTION AND USE THEREOF AS MEDICAMENTS LIPE, STS, ARSA CA2 2004/4885CA1 3065/4885CA12 2840/4885
US-20110123784-A1 WATER-SOLUBLE NEAR-INFRARED ABSORBING COLORING MATTERS AND AQUEOUS INKS CONTAINING SAME IK, RB1, COL1A1 CA2 1279/4885CA1 798/4885CA12 1243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.